Odyssey Therapeutics, Inc.

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Apogee TherapeuticsAPGE · BiotechnologyWaltham, United States

70% matchPublic

Apogee Therapeutics is a biotechnology company focused on the development of therapies for inflammatory and immunology diseases. The company is headquartered in Waltham, Massachusetts.

Ventyx Biosciences, Inc.BiotechnologyUnited States

70% matchPrivate

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.

Zenas BioPharma, Inc.ZBIO · BiotechWaltham, United States

69% matchPublicAI 0/100Green 0/100

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.